140 related articles for article (PubMed ID: 35858904)
1. R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis.
Othman T; Penaloza J; Zhang S; Daniel CE; Gaut D; Oliai C; Brem EA; Baweja A; Ly J; Reid J; Pinter-Brown L; Lee M; Abdulhaq H; Tuscano J
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e947-e957. PubMed ID: 35858904
[TBL] [Abstract][Full Text] [Related]
2. Dose-adjusted EPOCH-R vs. R-CHOP in frontline management of Waldeyer's ring diffuse large B-cell lymphoma: a retrospective study from a single institution.
Liang Y; Liu X; Yang J; Wang H; Piao Y; Wei L; Wang L
Chin Med J (Engl); 2023 Jan; 136(2):167-175. PubMed ID: 36780421
[TBL] [Abstract][Full Text] [Related]
3. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
Zhang XY; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Xu W
J Cancer Res Clin Oncol; 2019 Jan; 145(1):117-127. PubMed ID: 30327941
[TBL] [Abstract][Full Text] [Related]
4. DA-EPOCH-R improves the prognosis of patients with double-expressor lymphoma: A single-center retrospective study and meta-analysis.
Zhan J; Yang S; Zhang W; Zhou D; Zhang Y; Wang W; Wei C
Medicine (Baltimore); 2022 Sep; 101(38):e30620. PubMed ID: 36197215
[TBL] [Abstract][Full Text] [Related]
5. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma.
Chan EHL; Koh LP; Lee J; De Mel S; Jeyasekharan A; Liu X; Tang T; Lim ST; Tao M; Quek R; Farid Bin Harunal Ras M; Lee YS; Diong C; Tan D; Kim SJ; Chee YL; Poon LMM
Cancer Med; 2019 Aug; 8(10):4626-4632. PubMed ID: 31264808
[TBL] [Abstract][Full Text] [Related]
6. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Bartlett NL; Wilson WH; Jung SH; Hsi ED; Maurer MJ; Pederson LD; Polley MC; Pitcher BN; Cheson BD; Kahl BS; Friedberg JW; Staudt LM; Wagner-Johnston ND; Blum KA; Abramson JS; Reddy NM; Winter JN; Chang JE; Gopal AK; Chadburn A; Mathew S; Fisher RI; Richards KL; Schöder H; Zelenetz AD; Leonard JP
J Clin Oncol; 2019 Jul; 37(21):1790-1799. PubMed ID: 30939090
[TBL] [Abstract][Full Text] [Related]
7. Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective study.
Morgenstern Y; Aumann S; Goldschmidt N; Gatt ME; Nachmias B; Horowitz NA
Cancer Med; 2021 Dec; 10(24):8866-8875. PubMed ID: 34816617
[TBL] [Abstract][Full Text] [Related]
8. DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose?
Major A; Smith SM
Clin Adv Hematol Oncol; 2021 Nov; 19(11):698-709. PubMed ID: 34807015
[TBL] [Abstract][Full Text] [Related]
9. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
Shah NN; Szabo A; Huntington SF; Epperla N; Reddy N; Ganguly S; Vose J; Obiozor C; Faruqi F; Kovach AE; Costa LJ; Xavier AC; Okal R; Kanate AS; Ghosh N; Kharfan-Dabaja MA; Strelec L; Hamadani M; Fenske TS; Calzada O; Cohen JB; Chavez J; Svoboda J
Br J Haematol; 2018 Feb; 180(4):534-544. PubMed ID: 29265182
[TBL] [Abstract][Full Text] [Related]
10. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of people living with human immunodeficiency virus (HIV) with diffuse large B-cell lymphoma (DLBCL) in Shanghai, China.
Sun JJ; Liu L; Wang JR; Shen YZ; Qi TK; Wang ZY; Tang Y; Song W; Chen J; Zhang RF
Chin Med J (Engl); 2020 Dec; 133(23):2796-2802. PubMed ID: 33273327
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma.
Malenda A; Kołkowska-Leśniak A; Puła B; Długosz-Danecka M; Chełstowska M; Końska A; Giza A; Lech-Marańda E; Jurczak W; Warzocha K
Eur J Haematol; 2020 Jan; 104(1):59-66. PubMed ID: 31606909
[TBL] [Abstract][Full Text] [Related]
13. Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.
Dodero A; Guidetti A; Marino F; Tucci A; Barretta F; Re A; Balzarotti M; Carniti C; Monfrini C; Chiappella A; Cabras A; Facchetti F; Pennisi M; Rahal D; Monti V; Devizzi L; Miceli R; Cocito F; Farina L; Ricci F; Rossi G; Carlo-Stella C; Corradini P
Haematologica; 2022 May; 107(5):1153-1162. PubMed ID: 34289655
[TBL] [Abstract][Full Text] [Related]
14. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.
Devi K; Shaikh MU; Ali NB; Adil SN; Khan M; Soomar SM
Leuk Res Rep; 2021; 16():100284. PubMed ID: 34926144
[TBL] [Abstract][Full Text] [Related]
16. Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem).
Mitrovic Z; Dujmovic D; Jaksic O; Kinda SB; Gacina P; Perisa V; Prka Z; Dreta B; Galusic D; Holik H; Pejsa V; Aurer I
Eur J Haematol; 2023 Jun; 110(6):725-731. PubMed ID: 36941738
[TBL] [Abstract][Full Text] [Related]
17. Treatment options in primary mediastinal B cell lymphoma patients, retrospective multicentric analysis; a Turkısh oncology group study.
Acar R; Paydaş S; Yıldırım M; Kılıçarslan E; Sahın U; Dogan A; Guven DC; Ekıncı O; Tıglıoglu M; Erdogan I; Elıbol T; Kızıloz H; Aykan MB; Sayın S; Kaptan K; Soydan E; Gokmen A; Esen R; Barısta I; Albayrak M; Erturk I; Yıldız B; Keskın GY; Aylı M; Karadurmus N
J Cancer Res Ther; 2023 Apr; 19(Supplement):S138-S144. PubMed ID: 37147993
[TBL] [Abstract][Full Text] [Related]
18. Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas.
Weis TM; Marini BL; Nachar VR; Brown AM; Phillips TJ; Brown J; Wilcox RA; Kaminski MS; Devata S; Perissinotti AJ
Leuk Lymphoma; 2020 May; 61(5):1126-1132. PubMed ID: 31876206
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with
Ma Q; Chang Y; Li L; Li X; Wang X; Wu J; Fu X; Sun Z; Yu H; Zhang X; Zhou Z; Nan F; Li Z; Liu X; Zhao Q; Li Y; Zhang L; Zhang M; Zhang L
Cancer Manag Res; 2019; 11():1363-1372. PubMed ID: 30809101
[TBL] [Abstract][Full Text] [Related]
20. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]